Cynapsus Therapeutics Inc. (NASDAQ:CYNA) has been assigned an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have assigned a strong buy rating to the company. Cynapsus Therapeutics’ rating score has declined by 50% from 90 days ago as a result of various analysts’ ratings changes.

Analysts have set a 1-year consensus price objective of $36.50 for the company and are forecasting that the company will post ($0.75) EPS for the current quarter, according to Zacks. Zacks has also assigned Cynapsus Therapeutics an industry rank of 88 out of 265 based on the ratings given to its competitors.

A number of analysts have commented on CYNA shares. Noble Financial reiterated a “buy” rating and issued a $50.00 price target on shares of Cynapsus Therapeutics in a research note on Tuesday, August 30th. BMO Capital Markets set a $30.00 target price on shares of Cynapsus Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Finally, Janney Montgomery Scott began coverage on shares of Cynapsus Therapeutics in a research note on Wednesday, June 15th. They set a “buy” rating and a $24.00 target price for the company.

Shares of Cynapsus Therapeutics (NASDAQ:CYNA) opened at 40.20 on Monday. Cynapsus Therapeutics has a one year low of $10.54 and a one year high of $40.25. The company has a 50-day moving average price of $26.80 and a 200 day moving average price of $17.15. The firm’s market capitalization is $498.92 million.

Cynapsus Therapeutics (NASDAQ:CYNA) last announced its quarterly earnings results on Thursday, August 11th. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $1.60. Analysts expect that Cynapsus Therapeutics will post ($3.15) earnings per share for the current fiscal year.

Cynapsus Therapeutics Company Profile

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

5 Day Chart for NASDAQ:CYNA

Get a free copy of the Zacks research report on Cynapsus Therapeutics (CYNA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cynapsus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics Inc. and related companies with's FREE daily email newsletter.